MedTrace Logo

SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00005042 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2014-08-29

No results posted yet for this study

Summary

RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.

PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.

Conditions

  • Sarcoma

Interventions

DRUG

semaxanib

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • AIDS Malignancy Consortium

    lead NETWORK

Principal Investigators

  • Steven A. Miles, MD · UCLA Clinical AIDS Research and Education (CARE) Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2000-11-30
Completion
2000-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005042 on ClinicalTrials.gov